Oct 4 (Reuters) - Eli Lilly and Co said on Wednesday that the head of its diabetes and obesity division, Mike Mason, will retire by the end of the year after more than three decades with the drugmaker. (Reporting by Bhanvi Satija in Bengaluru; Editing by Savio D'Souza)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
865 USD | +1.77% | +4.06% | +48.39% |
05:39am | Eli Lilly's Alzheimer's Drug Gets Favorable Opinion from US FDA's Independent Panel | MT |
Jun. 10 | Eli Lilly exec expects obesity pill data in April 2025 | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+48.39% | 765B | |
-6.13% | 354B | |
+20.61% | 331B | |
+10.00% | 299B | |
+18.87% | 248B | |
-1.96% | 219B | |
+11.11% | 216B | |
+5.80% | 164B | |
-2.50% | 162B | |
+0.57% | 123B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Eli Lilly's head of diabetes and obesity unit to retire